Dainippon Sumitomo President Tada: Company En Route To 2017 Goal Of ¥450 Billion In Sales
This article was originally published in PharmAsia News
Executive Summary
With 2015 profit forecasts in double digits, Dainippon Sumitomo is moving steadily towards its mid-term goal of ¥450 billion ($5.5 billion) in sales and ¥80 billion by 2017, the company’s President Masayo Tada told Tokyo reporters on May 8.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.